File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Biology of hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleBiology of hepatocellular carcinoma
 
AuthorsPang, RWC2
Joh, JW1
Johnson, PJ4
Monden, M3
Pawlik, TM5
Poon, RTP2
 
KeywordsAngiogenesis
Biological factors
Biomarkers
Gene expression
Hepatocellular
Molecular
 
Issue Date2008
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
 
CitationAnnals Of Surgical Oncology, 2008, v. 15 n. 4, p. 962-971 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-007-9730-z
 
AbstractHepatocellular carcinoma (HCC) is a common cancer in the world due to high prevalence of hepatitis B or C virus infection. Research in recent years has uncovered important molecular pathways involved in development and progression of HCC. Several genetic aberrations and molecular mechanisms responsible for initiation of hepatocarcinogenesis have been identified. Novel biomarkers for HCC are being developed for better detection and prognostication. Alpha-fetoprotein, the conventional marker of HCC, has limited sensitivity and specificity. Serum levels of isoforms of AFP based on differential lectin binding of the glycan moiety appear to be more sensitive and specific than total AFP level in early detection of HCC. The clinical usefulness of other HCC biomarkers such as des-γ-carboxy prothrombin and glypican-3 are under investigation. HCC is an aggressive tumor with early vascular invasion and metastasis. Studies over the past two decades have elucidated the clinical predictors of outcome, leading to several staging systems for HCC based on clinical parameters. However, the predictive accuracy of clinical staging systems is limited. Recent studies suggested that biological factors may provide additional prognostic information. In particular, gene expression profiling appears to be a promising approach. Study of tumor angiogenesis in HCC reveals that the expression of angiogenic factors such as vascular endothelial growth factor and angiopoietins may also predict prognosis. The elucidation of tumor biology of HCC is of particular importance in the current era of rapid development of anti-cancer molecular targeting agents, which provide hope for an effective systemic therapy for HCC. © 2007 Society of Surgical Oncology.
 
ISSN1068-9265
2013 Impact Factor: 3.943
 
DOIhttp://dx.doi.org/10.1245/s10434-007-9730-z
 
ISI Accession Number IDWOS:000253896000004
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorPang, RWC
 
dc.contributor.authorJoh, JW
 
dc.contributor.authorJohnson, PJ
 
dc.contributor.authorMonden, M
 
dc.contributor.authorPawlik, TM
 
dc.contributor.authorPoon, RTP
 
dc.date.accessioned2010-09-06T07:38:13Z
 
dc.date.available2010-09-06T07:38:13Z
 
dc.date.issued2008
 
dc.description.abstractHepatocellular carcinoma (HCC) is a common cancer in the world due to high prevalence of hepatitis B or C virus infection. Research in recent years has uncovered important molecular pathways involved in development and progression of HCC. Several genetic aberrations and molecular mechanisms responsible for initiation of hepatocarcinogenesis have been identified. Novel biomarkers for HCC are being developed for better detection and prognostication. Alpha-fetoprotein, the conventional marker of HCC, has limited sensitivity and specificity. Serum levels of isoforms of AFP based on differential lectin binding of the glycan moiety appear to be more sensitive and specific than total AFP level in early detection of HCC. The clinical usefulness of other HCC biomarkers such as des-γ-carboxy prothrombin and glypican-3 are under investigation. HCC is an aggressive tumor with early vascular invasion and metastasis. Studies over the past two decades have elucidated the clinical predictors of outcome, leading to several staging systems for HCC based on clinical parameters. However, the predictive accuracy of clinical staging systems is limited. Recent studies suggested that biological factors may provide additional prognostic information. In particular, gene expression profiling appears to be a promising approach. Study of tumor angiogenesis in HCC reveals that the expression of angiogenic factors such as vascular endothelial growth factor and angiopoietins may also predict prognosis. The elucidation of tumor biology of HCC is of particular importance in the current era of rapid development of anti-cancer molecular targeting agents, which provide hope for an effective systemic therapy for HCC. © 2007 Society of Surgical Oncology.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationAnnals Of Surgical Oncology, 2008, v. 15 n. 4, p. 962-971 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-007-9730-z
 
dc.identifier.citeulike3978074
 
dc.identifier.doihttp://dx.doi.org/10.1245/s10434-007-9730-z
 
dc.identifier.epage971
 
dc.identifier.hkuros150869
 
dc.identifier.isiWOS:000253896000004
 
dc.identifier.issn1068-9265
2013 Impact Factor: 3.943
 
dc.identifier.issue4
 
dc.identifier.openurl
 
dc.identifier.pmid18236113
 
dc.identifier.scopuseid_2-s2.0-40549100994
 
dc.identifier.spage962
 
dc.identifier.urihttp://hdl.handle.net/10722/78014
 
dc.identifier.volume15
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAnnals of Surgical Oncology
 
dc.relation.referencesReferences in Scopus
 
dc.subjectAngiogenesis
 
dc.subjectBiological factors
 
dc.subjectBiomarkers
 
dc.subjectGene expression
 
dc.subjectHepatocellular
 
dc.subjectMolecular
 
dc.titleBiology of hepatocellular carcinoma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Pang, RWC</contributor.author>
<contributor.author>Joh, JW</contributor.author>
<contributor.author>Johnson, PJ</contributor.author>
<contributor.author>Monden, M</contributor.author>
<contributor.author>Pawlik, TM</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<date.accessioned>2010-09-06T07:38:13Z</date.accessioned>
<date.available>2010-09-06T07:38:13Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Annals Of Surgical Oncology, 2008, v. 15 n. 4, p. 962-971</identifier.citation>
<identifier.issn>1068-9265</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/78014</identifier.uri>
<description.abstract>Hepatocellular carcinoma (HCC) is a common cancer in the world due to high prevalence of hepatitis B or C virus infection. Research in recent years has uncovered important molecular pathways involved in development and progression of HCC. Several genetic aberrations and molecular mechanisms responsible for initiation of hepatocarcinogenesis have been identified. Novel biomarkers for HCC are being developed for better detection and prognostication. Alpha-fetoprotein, the conventional marker of HCC, has limited sensitivity and specificity. Serum levels of isoforms of AFP based on differential lectin binding of the glycan moiety appear to be more sensitive and specific than total AFP level in early detection of HCC. The clinical usefulness of other HCC biomarkers such as des-&#947;-carboxy prothrombin and glypican-3 are under investigation. HCC is an aggressive tumor with early vascular invasion and metastasis. Studies over the past two decades have elucidated the clinical predictors of outcome, leading to several staging systems for HCC based on clinical parameters. However, the predictive accuracy of clinical staging systems is limited. Recent studies suggested that biological factors may provide additional prognostic information. In particular, gene expression profiling appears to be a promising approach. Study of tumor angiogenesis in HCC reveals that the expression of angiogenic factors such as vascular endothelial growth factor and angiopoietins may also predict prognosis. The elucidation of tumor biology of HCC is of particular importance in the current era of rapid development of anti-cancer molecular targeting agents, which provide hope for an effective systemic therapy for HCC. &#169; 2007 Society of Surgical Oncology.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.annalssurgicaloncology.org</publisher>
<relation.ispartof>Annals of Surgical Oncology</relation.ispartof>
<subject>Angiogenesis</subject>
<subject>Biological factors</subject>
<subject>Biomarkers</subject>
<subject>Gene expression</subject>
<subject>Hepatocellular</subject>
<subject>Molecular</subject>
<title>Biology of hepatocellular carcinoma</title>
<type>Conference_Paper</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1068-9265&amp;volume=15&amp;issue=4&amp;spage=962&amp;epage=971&amp;date=2008&amp;atitle=Biology+of+hepatocellular+carcinoma</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1245/s10434-007-9730-z</identifier.doi>
<identifier.pmid>18236113</identifier.pmid>
<identifier.scopus>eid_2-s2.0-40549100994</identifier.scopus>
<identifier.hkuros>150869</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-40549100994&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>15</identifier.volume>
<identifier.issue>4</identifier.issue>
<identifier.spage>962</identifier.spage>
<identifier.epage>971</identifier.epage>
<identifier.isi>WOS:000253896000004</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.citeulike>3978074</identifier.citeulike>
</item>
Author Affiliations
  1. SungKyunKwan University, School of Medicine
  2. The University of Hong Kong
  3. Osaka University
  4. University of Birmingham
  5. The Johns Hopkins School of Medicine